X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Arformoterol Tartrate inhalation solution, EQ 0.015 mg Base/2 ml is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and emphysema.
Lead Product(s): Arformoterol Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Arformoterol Tartrate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2022
Details:
Provepharm acquired global rights of the Cetrorelix acetate from Calyptus and will take on all development activities and ultimately commercial distribution upon approval.
Lead Product(s): Cetrorelix Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cetrorelix Acetate-Generic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Provepharm Life Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 22, 2022
Details:
Cetrorelix Acetate for Injection, 0.25 mg/vial is indicated for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian stimulation.
Lead Product(s): Cetrorelix Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cetrorelix Acetate-Generic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
